CSI Laboratories PD-L1 Expression Assay
Jul 13, 2016
CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, has launched a PD-L1 (programmed death-ligand 1) immunohistochemical protein expression assay, which can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies. More specifically, the assay provides a specimen's PD-L1 tumor cell reactivity score, which can be used to identify patients who are more likely to respond to certain PD-1/PD-L1 inhibitor therapies.